In special, the anti-obesity and weight loss effects of telmisartan (AT1R blocker) are dependent to PPARδ [28], also fimasartan, a novel AT1R blocker, ameliorates nonalcoholic fatty liver disease through PPARδ activation [26]. The gene discussed is PPARD; the disease is metabolic dysfunction-associated steatotic liver disease.